T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know about these game-changing medications.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney problems.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.